

MÃ¼nevver Demir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5770162/publications.pdf>

Version: 2024-02-01

56
papers

1,659
citations

489802

18
h-index

371746

37
g-index

58
all docs

58
docs citations

58
times ranked

2630
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonalcoholic fatty liver disease is associated with a higher incidence of coeliac disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 328-331.	0.8	5
2	Shear wave elastography and shear wave dispersion imaging in primary biliary cholangitisâ€”a pilot study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 1235-1242.	1.1	10
3	Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. <i>Hepatology International</i> , 2022, 16, 359-370.	1.9	15
4	Complement activation induces excessive T cell cytotoxicity in severe COVID-19. <i>Cell</i> , 2022, 185, 493-512.e25.	13.5	122
5	The fecal mycobiome in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 788-799.	1.8	66
6	Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. <i>Current Atherosclerosis Reports</i> , 2022, 24, 533-546.	2.0	19
7	Perinatal Obesity Induces Hepatic Growth Restriction with Increased DNA Damage Response, Senescence, and Dysregulated Igf-1-Akt-Foxo1 Signaling in Male Offspring of Obese Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5609.	1.8	5
8	NAFLD and cardiovascular diseases: a clinical review. <i>Clinical Research in Cardiology</i> , 2021, 110, 921-937.	1.5	285
9	Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. <i>Neuroendocrinology</i> , 2021, 111, 217-236.	1.2	17
10	Targeting pathobionts for the treatment of alcoholâ€”associated liver disease. <i>Liver International</i> , 2021, 41, 239-240.	1.9	1
11	Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis. <i>JGH Open</i> , 2021, 5, 356-363.	0.7	0
12	From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1492.	1.8	16
13	Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 652172.	2.2	21
14	Shear Wave Elastography and Shear Wave Dispersion Imaging in the Assessment of Liver Disease in Alpha1-Antitrypsin Deficiency. <i>Diagnostics</i> , 2021, 11, 629.	1.3	4
15	Incidences of hypothyroidism and autoimmune thyroiditis are increased in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e1008-e1012.	0.8	6
16	Hypertension in NAFLD: An uncontrolled burden. <i>Journal of Hepatology</i> , 2021, 74, 1258-1260.	1.8	11
17	Combined analysis of gut microbiota, diet and <i>PNPLA3</i> polymorphism in biopsyâ€”proven nonâ€”alcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 1576-1591.	1.9	11
18	Variables associated with increased incidence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002243.	1.2	9

#	ARTICLE	IF	CITATIONS
19	Maternal Exercise Mediates Hepatic Metabolic Programming via Activation of AMPK-PGC1 α Axis in the Offspring of Obese Mothers. <i>Cells</i> , 2021, 10, 1247.	1.8	15
20	The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3392.	1.0	14
21	Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies. <i>Clinical and Translational Science</i> , 2021, 14, 1853-1863.	1.5	6
22	In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4993.	1.8	8
23	Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programming. <i>Scientific Reports</i> , 2020, 10, 15424.	1.6	18
24	Circulating levels of microRNA193a-5p predict outcome in early stage hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0239386.	1.1	11
25	Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2881.	1.0	8
26	Skeletal Muscle Composition Predicts Outcome in Critically Ill Patients. , 2020, 2, e0171.		34
27	Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools. <i>Scientific Reports</i> , 2020, 10, 9385.	1.6	20
28	Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 159, 1839-1852.	0.6	103
29	Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1647.	1.0	6
30	Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. <i>Hepatic Oncology</i> , 2020, 7, HEP20.	4.2	30
31	The role of the innate immune system in the development and treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2020, 7, HEP17.	4.2	46
32	Cytolysin-positive <i>Enterococcus faecalis</i> is not increased in patients with non-alcoholic steatohepatitis. <i>Liver International</i> , 2020, 40, 860-865.	1.9	29
33	Hepatocellular carcinoma surveillance with liver imaging is not associated with improved survival. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 222-227.	0.6	6
34	Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1969-1977.	1.4	27
35	High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. <i>Hepatology Communications</i> , 2020, 4, 681-695.	2.0	28
36	Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. <i>PLoS ONE</i> , 2020, 15, e0244504.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 781-793.	3.7	58
38	Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers. <i>Journal of Human Genetics</i> , 2018, 63, 621-626.	1.1	29
39	Prevalence of Anti-HBs Without Anti-HBc Among HIV-Infected Adults Initiating Antiretroviral Therapy in Lilongwe, Malawi. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, e14-e15.	0.9	3
40	Serrated polyposis syndrome may go undiagnosed even in structured colorectal cancer screening programmes performed by endoscopists with otherwise good quality indices. <i>Gut</i> , 2018, 67, 1746-1747.	6.1	2
41	The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm. <i>Hepatology</i> , 2017, 66, 666-667.	3.6	7
42	Real-world risk score for hepatocellular carcinoma risk prediction in CHBV: a validation outside of Asia. <i>Gut</i> , 2017, 66, 1346-1347.	6.1	3
43	Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1235-1240.	0.8	3
44	Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. <i>Journal of Lipid Research</i> , 2017, 58, 247-255.	2.0	159
45	HIV/Hepatitis C Virus Co-infection among Adults Beginning Antiretroviral Therapy, Malawi. <i>Emerging Infectious Diseases</i> , 2016, 22, 2018-2020.	2.0	4
46	Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. <i>Medicine (United States)</i> , 2016, 95, e4602.	0.4	6
47	Glutathione peroxidase 4 is reversibly induced by HCV to control lipid peroxidation and to increase virion infectivity. <i>Gut</i> , 2016, 65, 144-154.	6.1	45
48	Circadian Variation in Arterial Blood Pressure and Glaucomatous Optic Neuropathyâ€”A Systematic Review and Meta-Analysis. <i>American Journal of Hypertension</i> , 2015, 28, 1077-1082.	1.0	69
49	Nonalcoholic fatty liver disease â€” current status and future directions. <i>Journal of Digestive Diseases</i> , 2015, 16, 541-557.	0.7	80
50	Cost of treating hepatitis C in Germany. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1278-1285.	0.8	9
51	The laparoscopic approach for radiofrequency ablation of hepatocellular carcinomaâ€”indication, technique and results. <i>Langenbeck's Archives of Surgery</i> , 2013, 398, 47-53.	0.8	41
52	Telmisartan Plus Propranolol Improves Liver Fibrosis and Bile Duct Proliferation in the PSC-Like Abcb4âˆ’/âˆ’ Mouse Model. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1271-1281.	1.1	10
53	Stepwise Combination of Simple Noninvasive Fibrosis Scoring Systems Increases Diagnostic Accuracy in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 719-726.	1.1	33
54	NIKEI: A New Inexpensive and Non-Invasive Scoring System to Exclude Advanced Fibrosis in Patients with NAFLD. <i>PLoS ONE</i> , 2013, 8, e58360.	1.1	36

#	ARTICLE	IF	CITATIONS
55	Neighbor of Punc E 11: Expression Pattern of the New Hepatic Stem/Progenitor Cell Marker During Murine Liver Development. <i>Stem Cells and Development</i> , 2012, 21, 2656-2666.	1.1	14
56	Hepatocyte expression of angiotensin II type 1 receptor is downregulated in advanced human liver fibrosis. <i>Liver International</i> , 2009, 29, 384-391.	1.9	11